Alnylam Pharmcaeuticals, a company specializing in RNA-interference therapeutics, talks to BioPharm International's Amy Ritter about its RNAi delivery system and its early-stage clinical pipeline.
Ligand-binding assays are fundamental to characterizing biosimilars.
The European Commission’s new structure has sparked controversy about its allocation of responsibilities and the impact on the development and approval of new medicines.
Nelson Patterson has been elected to Pharma & Biopharma Outsourcing Association board.
There are significant differences between small molecules and biologics fill/finish capacity.
New organization offers support to contract research organizations and contract manufacturing organizations in the New England area.
Outsourcing is taking on a greater role in the biopharmaceutical manufacturing industry.
The agency creates an electronic central repository to facilitate drug safety assessment reports.
FDA guidance discusses factors to consider in evaluation of photosafety and describes nonclinical photosafety tests.
Dr. Robert Califf is appointed FDA Deputy Commissioner for Medical Products and Tobacco.